Breakthroughs on the Clinical Management of Headache and Questions That Need to Be Solved

Overview

Journal Ibrain

Specialty Neurology

Date 2023 Oct 3

PMID 37786564

Authors

Yu-Cong Liu

Ting-Ting Yang

Jing Li

Hui-Chan Xu

Shun-Lian Li

Liu-Lin Xiong

Affiliations

Soon will be listed here.

Abstract

Headache is a common refractory disorder among adults, especially in females, which can lower the quality of life in patients and increase medical costs. Nearly 90% of people have been affected by headache disorders during their lifetime. The severe situation of headaches has drawn the attention of researchers in recent years. Although the mechanism of headache has not been fully understood by us, there are many effective preventive drugs and treatments available. This review is aimed to sum up the progress in clinical trials of headaches in the past 5 years.

Citing Articles

Stellate ganglion intervention for chronic pain: A review.

Luo Q, Wen S, Tan X, Yi X, Cao S Ibrain. 2023; 8(2):210-218.

PMID: 37786891 PMC: 10529017. DOI: 10.1002/ibra.12047.

Breakthroughs on the clinical management of headache and questions that need to be solved.

Liu Y, Yang T, Li J, Xu H, Li S, Xiong L Ibrain. 2023; 7(4):298-308.

PMID: 37786564 PMC: 10529177. DOI: 10.1002/ibra.12003.

References

Kurian A, Reghunadhan I, Thilak P, Soman I, Nair U . Short-term Efficacy and Safety of Topical β-Blockers (Timolol Maleate Ophthalmic Solution, 0.5%) in Acute Migraine: A Randomized Crossover Trial. JAMA Ophthalmol. 2020; 138(11):1160-1166. PMC: 7530820. DOI: 10.1001/jamaophthalmol.2020.3676. View

Seminowicz D, Burrowes S, Kearson A, Zhang J, Krimmel S, Samawi L . Enhanced mindfulness-based stress reduction in episodic migraine: a randomized clinical trial with magnetic resonance imaging outcomes. Pain. 2020; 161(8):1837-1846. PMC: 7487005. DOI: 10.1097/j.pain.0000000000001860. View

Mulleners W, Kim B, Lainez M, Lanteri-Minet M, Pozo-Rosich P, Wang S . Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020; 19(10):814-825. DOI: 10.1016/S1474-4422(20)30279-9. View

Kudrow D, Pascual J, Winner P, Dodick D, Tepper S, Reuter U . Vascular safety of erenumab for migraine prevention. Neurology. 2019; 94(5):e497-e510. PMC: 7080286. DOI: 10.1212/WNL.0000000000008743. View

Langford D, Bailey A, Chanda M, Clarke S, Drummond T, Echols S . Coding of facial expressions of pain in the laboratory mouse. Nat Methods. 2010; 7(6):447-9. DOI: 10.1038/nmeth.1455. View

Chen S, Chang Y, Chou C, Juan C, Lee H, Chen L . Circulating microRNAs Associated With Reversible Cerebral Vasoconstriction Syndrome. Ann Neurol. 2020; 89(3):459-473. DOI: 10.1002/ana.25965. View

Stephens G, Derry S, Moore R . Paracetamol (acetaminophen) for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev. 2016; (6):CD011889. PMC: 6457822. DOI: 10.1002/14651858.CD011889.pub2. View

Yarnitsky D, Volokh L, Ironi A, Weller B, Shor M, Shifrin A . Nonpainful remote electrical stimulation alleviates episodic migraine pain. Neurology. 2017; 88(13):1250-1255. DOI: 10.1212/WNL.0000000000003760. View

Goadsby P, Dodick D, Leone M, Bardos J, Oakes T, Millen B . Trial of Galcanezumab in Prevention of Episodic Cluster Headache. N Engl J Med. 2019; 381(2):132-141. DOI: 10.1056/NEJMoa1813440. View

10.

Christensen C, Younis S, Lindberg U, de Koning P, Tolnai D, Paulson O . Intradural artery dilation during experimentally induced migraine attacks. Pain. 2020; 162(1):176-183. DOI: 10.1097/j.pain.0000000000002008. View

11.

Friedman B, Irizarry E, Cain D, Caradonna A, Minen M, Solorzano C . Randomized Study of Metoclopramide Plus Diphenhydramine for Acute Posttraumatic Headache. Neurology. 2021; 96(18):e2323-e2331. PMC: 8166438. DOI: 10.1212/WNL.0000000000011822. View

12.

Chen L, Zhang Z, Chen W, Whelton P, Appel L . Lower Sodium Intake and Risk of Headaches: Results From the Trial of Nonpharmacologic Interventions in the Elderly. Am J Public Health. 2016; 106(7):1270-5. PMC: 4902761. DOI: 10.2105/AJPH.2016.303143. View

13.

Schwedt T, Kuruppu D, Dong Y, Standley K, Yunes-Medina L, Pearlman E . Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J Headache Pain. 2021; 22(1):15. PMC: 7992932. DOI: 10.1186/s10194-021-01230-w. View

14.

Villalon C, Centurion D . Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol. 2007; 376(1-2):45-63. DOI: 10.1007/s00210-007-0179-1. View

15.

Yuan H, Silberstein S . The Use of Botulinum Toxin in the Management of Headache Disorders. Handb Exp Pharmacol. 2020; 263:227-249. DOI: 10.1007/164_2020_365. View

16.

Arngrim N, Hougaard A, Schytz H, Vestergaard M, Britze J, Amin F . Effect of hypoxia on BOLD fMRI response and total cerebral blood flow in migraine with aura patients. J Cereb Blood Flow Metab. 2017; 39(4):680-689. PMC: 6446416. DOI: 10.1177/0271678X17719430. View

17.

Tepper S, Ashina M, Reuter U, Hallstrom Y, Broessner G, Bonner J . Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials. J Headache Pain. 2021; 22(1):81. PMC: 8299690. DOI: 10.1186/s10194-021-01292-w. View

18.

Kuca B, Silberstein S, Wietecha L, Berg P, Dozier G, Lipton R . Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018; 91(24):e2222-e2232. PMC: 6329326. DOI: 10.1212/WNL.0000000000006641. View

19.

Latev A, Friedman B, Irizarry E, Solorzano C, Restivo A, Chertoff A . A Randomized Trial of a Long-Acting Depot Corticosteroid Versus Dexamethasone to Prevent Headache Recurrence Among Patients With Acute Migraine Who Are Discharged From an Emergency Department. Ann Emerg Med. 2018; 73(2):141-149. DOI: 10.1016/j.annemergmed.2018.09.028. View

20.

Zirovich M, Pangarkar S, Manh C, Chen L, Vangala S, Elashoff D . Botulinum Toxin Type A for the Treatment of Post-traumatic Headache: A Randomized, Placebo-Controlled, Cross-over Study. Mil Med. 2020; 186(5-6):493-499. DOI: 10.1093/milmed/usaa391. View